Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Cash from Investing Activities (2022 - 2024)

Historic Cash from Investing Activities for Addex Therapeutics (ADXN) over the last 3 years, with Q4 2024 value amounting to -$5320.8 billion.

  • Addex Therapeutics' Cash from Investing Activities fell 8382703.21% to -$5320.8 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $64.7 billion, marking a year-over-year increase of 8976828.61%. This contributed to the annual value of $5.3 million for FY2024, which is 6941078.14% up from last year.
  • Latest data reveals that Addex Therapeutics reported Cash from Investing Activities of -$5320.8 billion as of Q4 2024, which was down 8382703.21% from $5379.9 billion recorded in Q3 2024.
  • In the past 5 years, Addex Therapeutics' Cash from Investing Activities registered a high of $5379.9 billion during Q3 2024, and its lowest value of -$5320.8 billion during Q4 2024.
  • For the 3-year period, Addex Therapeutics' Cash from Investing Activities averaged around $8.5 billion, with its median value being -$2669.4 (2023).
  • In the last 5 years, Addex Therapeutics' Cash from Investing Activities skyrocketed by 6802351246492.38% in 2023 and then tumbled by 8382703.21% in 2024.
  • Addex Therapeutics' Cash from Investing Activities (Quarter) stood at -$9.34 in 2022, then skyrocketed by 68023512464.92% to $6.4 billion in 2023, then plummeted by 83827.03% to -$5320.8 billion in 2024.
  • Its Cash from Investing Activities was -$5320.8 billion in Q4 2024, compared to $5379.9 billion in Q3 2024 and $6.4 billion in Q4 2023.